Turk J Med Sci
-
Multicenter Study
Evaluation of efficacy and safety of pirfenidone 200 mg tablets in patients with idiopathic pulmonary fibrosis in a real-life setting.
Phase III trials have demonstrated a significant efficacy and an acceptable safety for pirfenidone in patients having mild to moderate idiopathic pulmonary fibrosis (IPF). Real-life data on the use of pirfenidone 200 mg tablets are limited. This study aimed to investigate the efficacy and safety of pirfenidone 200 mg tablets for the treatment of IPF in a real-life setting. ⋯ Pirfenidone 200 mg was effective and well tolerated and associated with relatively mild and manageable AEs in IPF patien
-
Multicenter Study
WARFARIN IS ASSOCIATED WITH THE RISK OF VASCULAR CALCIFICATION IN ABDOMINAL AORTA IN HEMODIALYSIS PATIENTS: A MULTICENTER CASE-CONTROL STUDY.
Vascular calcifications (VCs), recognized risk factor for increased mortality, are highly prevalent in hemodialysis (HD) patients. We aimed to investigate the relation between VC and warfarin use with plain radiography. ⋯ In this study, we found that warfarin is associated to vascular calcifications, especially in aorta of HD patients.
-
Multicenter Study
High Mobility Group Box-1 Levels may be associated with disease activity of Behcet's Disease.
High mobility group box- 1 (HMGB- 1) is a nuclear protein acting as a proinflammatory molecule. The serum HMGB- 1 levels were found elevated in chronic inflammatory diseases. In this cross-sectional study, serum HMGB- 1 levels in Behcet's disease (BD) patients and healthy controls (HC) were studied. Also, its association with disease activity scores and clinical findings were evaluated. ⋯ HMGB - 1 may play a role in the development of BD. Also, due to its positive correlation with disease activity indices, it can be used as a novel disease activity parameter in BD.
-
Multicenter Study
Rituximab treatment for difficult-to-treat nephrotic syndrome in children: a multicenter, retrospective study.
This study aimed to evaluate the efficacy of rituximab in children with difficult-to-treat nephrotic syndrome, considering the type of disease (steroid-sensitive or –resistant) and the dosing regimen. ⋯ The current study reveals that rituximab therapy may provide a lower relapse rate and prolonged relapse-free survival in the steroid-sensitive group, increased remission rates in the steroid-resistant group, and a significant number of drug-free patients in both groups. The optimal regimen for initial treatment and maintenance needs to be determined.
-
Multicenter Study
Evaluation of Extensively Drug-Resistant Gram Negative Bacteremia among Solid-Organ Transplant Recipients: A Multicenter Study.
The aim of this study is to evaluate the distribution, sources, clinical features, and mortality rates of bacteremia due to evaluation of extensively drug-resistant (XDR) gram negative among solid-organ transplant (SOT) recipients. ⋯ Difficult-to-treat infections due to XDR bacteria in SOT recipients shadow the success of transplantation. Central venous catheters seem to be the main risk factor. Judicious use of medical devices is of pivotal importance.